LV12493B - PHARMACEUTICAL COMPOSITION CONTAINING PLASMA BLOOD - Google Patents

PHARMACEUTICAL COMPOSITION CONTAINING PLASMA BLOOD Download PDF

Info

Publication number: LV12493B
Authority: LV; Latvia
Prior art keywords: water; product; serum albumin; protein fraction; solution
Prior art date: 1997-09-18

Application number

LVP-00-38A

Other languages

English (en)

Latvian (lv)

Other versions

LV12493A (en

Inventor

Lajos HEGED�S

Krisztina Krempels

Krisztina Paal

Gabor PETH�

Original Assignee

Human Rt.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-18

Filing date

2000-03-14

Publication date

2001-01-20

2000-03-14 Application filed by Human Rt. filed Critical Human Rt.

2000-06-20 Publication of LV12493A publication Critical patent/LV12493A/xx

2001-01-20 Publication of LV12493B publication Critical patent/LV12493B/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 47
102000004506 Blood Proteins Human genes 0.000 title claims abstract description 19
108010017384 Blood Proteins Proteins 0.000 title claims abstract description 19
102000004169 proteins and genes Human genes 0.000 claims abstract description 61
108090000623 proteins and genes Proteins 0.000 claims abstract description 61
239000013543 active substance Substances 0.000 claims abstract description 58
108010058237 plasma protein fraction Proteins 0.000 claims abstract description 53
229940081857 plasma protein fraction Drugs 0.000 claims abstract description 53
238000000034 method Methods 0.000 claims abstract description 52
239000007787 solid Substances 0.000 claims abstract description 50
230000008569 process Effects 0.000 claims abstract description 19
238000002360 preparation method Methods 0.000 claims abstract description 17
239000007788 liquid Substances 0.000 claims abstract description 6
239000000243 solution Substances 0.000 claims description 137
239000000047 product Substances 0.000 claims description 82
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 67
108091006905 Human Serum Albumin Proteins 0.000 claims description 66
102000008100 Human Serum Albumin Human genes 0.000 claims description 66
229930012538 Paclitaxel Natural products 0.000 claims description 63
229960001592 paclitaxel Drugs 0.000 claims description 63
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 63
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 55
239000000203 mixture Substances 0.000 claims description 53
239000004480 active ingredient Substances 0.000 claims description 40
102000014150 Interferons Human genes 0.000 claims description 36
108010050904 Interferons Proteins 0.000 claims description 36
229940079322 interferon Drugs 0.000 claims description 35
238000009472 formulation Methods 0.000 claims description 34
102000003886 Glycoproteins Human genes 0.000 claims description 33
108090000288 Glycoproteins Proteins 0.000 claims description 33
102000015696 Interleukins Human genes 0.000 claims description 33
108010063738 Interleukins Proteins 0.000 claims description 33
239000000126 substance Substances 0.000 claims description 33
108060003951 Immunoglobulin Proteins 0.000 claims description 31
102000018358 immunoglobulin Human genes 0.000 claims description 31
102000007562 Serum Albumin Human genes 0.000 claims description 30
108010071390 Serum Albumin Proteins 0.000 claims description 30
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 28
229930105110 Cyclosporin A Natural products 0.000 claims description 28
108010036949 Cyclosporine Proteins 0.000 claims description 27
OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 claims description 27
229960004134 propofol Drugs 0.000 claims description 27
108010074605 gamma-Globulins Proteins 0.000 claims description 26
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 25
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 23
229960003942 amphotericin b Drugs 0.000 claims description 23
102000009027 Albumins Human genes 0.000 claims description 22
108010088751 Albumins Proteins 0.000 claims description 22
239000002904 solvent Substances 0.000 claims description 21
-1 taxonide Substances 0.000 claims description 21
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 20
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 20
229940127093 camptothecin Drugs 0.000 claims description 20
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 20
239000003960 organic solvent Substances 0.000 claims description 20
229960000623 carbamazepine Drugs 0.000 claims description 18
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 18
239000003381 stabilizer Substances 0.000 claims description 18
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 17
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 16
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 16
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 16
238000011282 treatment Methods 0.000 claims description 16
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 15
239000007864 aqueous solution Substances 0.000 claims description 14
230000001225 therapeutic effect Effects 0.000 claims description 14
239000000654 additive Substances 0.000 claims description 13
239000000872 buffer Substances 0.000 claims description 13
239000012141 concentrate Substances 0.000 claims description 13
239000003814 drug Substances 0.000 claims description 13
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 12
BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 11
229960002509 miconazole Drugs 0.000 claims description 11
230000004845 protein aggregation Effects 0.000 claims description 11
238000000108 ultra-filtration Methods 0.000 claims description 11
HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims description 10
NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 10
230000000996 additive effect Effects 0.000 claims description 10
229960002170 azathioprine Drugs 0.000 claims description 10
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 10
229960001265 ciclosporin Drugs 0.000 claims description 10
229960003627 gemfibrozil Drugs 0.000 claims description 10
229960000311 ritonavir Drugs 0.000 claims description 10
NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 10
241001465754 Metazoa Species 0.000 claims description 8
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 8
229960003387 progesterone Drugs 0.000 claims description 8
239000000186 progesterone Substances 0.000 claims description 8
229960001967 tacrolimus Drugs 0.000 claims description 8
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 8
229960001603 tamoxifen Drugs 0.000 claims description 8
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 7
VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 claims description 7
JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 claims description 7
PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 claims description 7
NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 7
239000003146 anticoagulant agent Substances 0.000 claims description 7
239000001961 anticonvulsive agent Substances 0.000 claims description 7
229960001671 azapropazone Drugs 0.000 claims description 7
WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 claims description 7
229960002729 bromazepam Drugs 0.000 claims description 7
DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims description 7
229960003120 clonazepam Drugs 0.000 claims description 7
229960003529 diazepam Drugs 0.000 claims description 7
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 7
229960001912 dicoumarol Drugs 0.000 claims description 7
DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 claims description 7
HIZKPJUTKKJDGA-UHFFFAOYSA-N dicumarol Natural products O=C1OC2=CC=CC=C2C(=O)C1CC1C(=O)C2=CC=CC=C2OC1=O HIZKPJUTKKJDGA-UHFFFAOYSA-N 0.000 claims description 7
WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 claims description 7
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 7
229960002768 dipyridamole Drugs 0.000 claims description 7
UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 claims description 7
229960001066 disopyramide Drugs 0.000 claims description 7
229960002200 flunitrazepam Drugs 0.000 claims description 7
238000004108 freeze drying Methods 0.000 claims description 7
229960004125 ketoconazole Drugs 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
229960000916 niflumic acid Drugs 0.000 claims description 7
ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 claims description 7
229960004535 oxazepam Drugs 0.000 claims description 7
239000000546 pharmaceutical excipient Substances 0.000 claims description 7
239000011780 sodium chloride Substances 0.000 claims description 7
229960003329 sulfinpyrazone Drugs 0.000 claims description 7
MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 claims description 7
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 claims description 6
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 6
125000002252 acyl group Chemical group 0.000 claims description 6
FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 claims description 6
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 6
229960002036 phenytoin Drugs 0.000 claims description 6
239000000600 sorbitol Substances 0.000 claims description 6
229960003604 testosterone Drugs 0.000 claims description 6
229960000604 valproic acid Drugs 0.000 claims description 6
229960005080 warfarin Drugs 0.000 claims description 6
PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims description 6
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
229930195725 Mannitol Natural products 0.000 claims description 5
239000000824 cytostatic agent Substances 0.000 claims description 5
230000001085 cytostatic effect Effects 0.000 claims description 5
239000001257 hydrogen Substances 0.000 claims description 5
229910052739 hydrogen Inorganic materials 0.000 claims description 5
239000000594 mannitol Substances 0.000 claims description 5
235000010355 mannitol Nutrition 0.000 claims description 5
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical group NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 4
PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 claims description 4
230000000202 analgesic effect Effects 0.000 claims description 4
239000003098 androgen Substances 0.000 claims description 4
230000003556 anti-epileptic effect Effects 0.000 claims description 4
229940127219 anticoagulant drug Drugs 0.000 claims description 4
229940121375 antifungal agent Drugs 0.000 claims description 4
230000003177 cardiotonic effect Effects 0.000 claims description 4
239000003218 coronary vasodilator agent Substances 0.000 claims description 4
238000000502 dialysis Methods 0.000 claims description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
230000000147 hypnotic effect Effects 0.000 claims description 4
230000000087 stabilizing effect Effects 0.000 claims description 4
229940088594 vitamin Drugs 0.000 claims description 4
239000011782 vitamin Substances 0.000 claims description 4
229930003231 vitamin Natural products 0.000 claims description 4
235000013343 vitamin Nutrition 0.000 claims description 4
150000003722 vitamin derivatives Chemical class 0.000 claims description 4
125000001931 aliphatic group Chemical class 0.000 claims description 3
230000001773 anti-convulsant effect Effects 0.000 claims description 3
229960003965 antiepileptics Drugs 0.000 claims description 3
238000007865 diluting Methods 0.000 claims description 3
239000000825 pharmaceutical preparation Substances 0.000 claims description 3
229940127557 pharmaceutical product Drugs 0.000 claims description 3
239000003504 photosensitizing agent Substances 0.000 claims description 3
239000003270 steroid hormone Substances 0.000 claims description 3
229940123635 Lipid peroxidase inhibitor Drugs 0.000 claims description 2
239000003242 anti bacterial agent Substances 0.000 claims description 2
230000003110 anti-inflammatory effect Effects 0.000 claims description 2
230000000840 anti-viral effect Effects 0.000 claims description 2
229960003444 immunosuppressant agent Drugs 0.000 claims description 2
230000001861 immunosuppressant effect Effects 0.000 claims description 2
239000003018 immunosuppressive agent Substances 0.000 claims description 2
239000012263 liquid product Substances 0.000 claims description 2
238000007911 parenteral administration Methods 0.000 claims 3
230000003449 preventive effect Effects 0.000 claims 3
WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 claims 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical class O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
239000003795 chemical substances by application Substances 0.000 claims 2
229960000648 digitoxin Drugs 0.000 claims 2
235000011187 glycerol Nutrition 0.000 claims 2
229920005862 polyol Polymers 0.000 claims 2
150000003077 polyols Chemical class 0.000 claims 2
229940124272 protein stabilizer Drugs 0.000 claims 2
LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical group CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 claims 2
MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 claims 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
239000003416 antiarrhythmic agent Substances 0.000 claims 1
229940088710 antibiotic agent Drugs 0.000 claims 1
239000003429 antifungal agent Substances 0.000 claims 1
238000011026 diafiltration Methods 0.000 claims 1
239000003326 hypnotic agent Substances 0.000 claims 1
238000002156 mixing Methods 0.000 claims 1
239000006201 parenteral dosage form Substances 0.000 claims 1
230000002265 prevention Effects 0.000 claims 1
239000006104 solid solution Substances 0.000 claims 1
229960004492 suprofen Drugs 0.000 claims 1
230000002485 urinary effect Effects 0.000 claims 1
230000027455 binding Effects 0.000 abstract description 63
230000002776 aggregation Effects 0.000 abstract description 39
238000004220 aggregation Methods 0.000 abstract description 39
235000018102 proteins Nutrition 0.000 description 53
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
150000001875 compounds Chemical class 0.000 description 20
238000004128 high performance liquid chromatography Methods 0.000 description 16
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 16
239000000706 filtrate Substances 0.000 description 14
239000012465 retentate Substances 0.000 description 14
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 8
238000001514 detection method Methods 0.000 description 8
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 8
239000012071 phase Substances 0.000 description 8
239000008389 polyethoxylated castor oil Substances 0.000 description 8
239000003643 water by type Substances 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
229940079593 drug Drugs 0.000 description 6
230000014759 maintenance of location Effects 0.000 description 6
239000012528 membrane Substances 0.000 description 6
RBKASMJPSJDQKY-RBFSKHHSSA-N tirilazad Chemical compound O=C([C@@H]1[C@@]2(C)CC=C3[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)CN(CC1)CCN1C(N=1)=CC(N2CCCC2)=NC=1N1CCCC1 RBKASMJPSJDQKY-RBFSKHHSSA-N 0.000 description 6
229960005155 tirilazad Drugs 0.000 description 6
FMHHVULEAZTJMA-UHFFFAOYSA-N trioxsalen Chemical compound CC1=CC(=O)OC2=C1C=C1C=C(C)OC1=C2C FMHHVULEAZTJMA-UHFFFAOYSA-N 0.000 description 6
229960000850 trioxysalen Drugs 0.000 description 6
238000004458 analytical method Methods 0.000 description 5
238000003556 assay Methods 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
230000000052 comparative effect Effects 0.000 description 5
239000012153 distilled water Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000013467 fragmentation Methods 0.000 description 5
238000006062 fragmentation reaction Methods 0.000 description 5
229960002695 phenobarbital Drugs 0.000 description 5
MDKGKXOCJGEUJW-UHFFFAOYSA-N suprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-UHFFFAOYSA-N 0.000 description 5
MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 5
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
206010006187 Breast cancer Diseases 0.000 description 4
208000026310 Breast neoplasm Diseases 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
206010020751 Hypersensitivity Diseases 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
241000700159 Rattus Species 0.000 description 4
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 4
201000008275 breast carcinoma Diseases 0.000 description 4
239000004359 castor oil Substances 0.000 description 4
235000019438 castor oil Nutrition 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
229910001873 dinitrogen Inorganic materials 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
235000019253 formic acid Nutrition 0.000 description 4
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
229960001340 histamine Drugs 0.000 description 4
238000001819 mass spectrum Methods 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
239000012265 solid product Substances 0.000 description 4
150000005846 sugar alcohols Polymers 0.000 description 4
231100000331 toxic Toxicity 0.000 description 4
230000002588 toxic effect Effects 0.000 description 4
239000008215 water for injection Substances 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 3
230000003288 anthiarrhythmic effect Effects 0.000 description 3
230000000843 anti-fungal effect Effects 0.000 description 3
230000002785 anti-thrombosis Effects 0.000 description 3
239000002249 anxiolytic agent Substances 0.000 description 3
230000000949 anxiolytic effect Effects 0.000 description 3
230000003115 biocidal effect Effects 0.000 description 3
SKKTUOZKZKCGTB-UHFFFAOYSA-N butyl carbamate Chemical compound CCCCOC(N)=O SKKTUOZKZKCGTB-UHFFFAOYSA-N 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
208000025113 myeloid leukemia Diseases 0.000 description 3
239000000583 progesterone congener Substances 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
230000003424 uricosuric effect Effects 0.000 description 3
229930183010 Amphotericin Natural products 0.000 description 2
QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
DZTHIGRZJZPRDV-UHFFFAOYSA-N N-acetyltryptophan Chemical compound C1=CC=C2C(CC(NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-UHFFFAOYSA-N 0.000 description 2
229940123742 Peroxidase inhibitor Drugs 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
229940009444 amphotericin Drugs 0.000 description 2
230000001028 anti-proliverative effect Effects 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
238000004891 communication Methods 0.000 description 2
229930182912 cyclosporin Natural products 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
229960004884 fluconazole Drugs 0.000 description 2
RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 2
210000003918 fraction a Anatomy 0.000 description 2
230000006698 induction Effects 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
101100235626 Caenorhabditis elegans hlb-1 gene Proteins 0.000 description 1
108010077544 Chromatin Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
108010030471 Histamine N-methyltransferase Proteins 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010024264 Lethargy Diseases 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010039238 Rouleaux formation Diseases 0.000 description 1
206010047141 Vasodilatation Diseases 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000003513 alkali Substances 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
235000021120 animal protein Nutrition 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229940088623 biologically active substance Drugs 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
DFFDSQBEGQFJJU-UHFFFAOYSA-N butyl hydrogen carbonate Chemical compound CCCCOC(O)=O DFFDSQBEGQFJJU-UHFFFAOYSA-N 0.000 description 1
150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
210000003483 chromatin Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
231100000086 high toxicity Toxicity 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000004264 monolayer culture Methods 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
238000009928 pasteurization Methods 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000009101 premedication Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
238000005464 sample preparation method Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000008279 sol Substances 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
229960001278 teniposide Drugs 0.000 description 1
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
231100000701 toxic element Toxicity 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Inorganic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Oncology (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LVP-00-38A 1997-09-18 2000-03-14 PHARMACEUTICAL COMPOSITION CONTAINING PLASMA BLOOD LV12493B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU9701554A HUP9701554D0 (en)	1997-09-18	1997-09-18	Pharmaceutical composition containing plazma proteins
PCT/HU1998/000086 WO1999013914A1 (en)	1997-09-18	1998-09-17	Pharmaceutical compositions containing plasma protein

Publications (2)

Publication Number	Publication Date
LV12493A LV12493A (en)	2000-06-20
LV12493B true LV12493B (en)	2001-01-20

Family

ID=90014222

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-00-38A LV12493B (en)	1997-09-18	2000-03-14	PHARMACEUTICAL COMPOSITION CONTAINING PLASMA BLOOD

Country Status (33)

Country	Link
US (5)	US6743826B1 (de)
EP (1)	EP0981375B1 (de)
JP (1)	JP2001508806A (de)
KR (1)	KR100587962B1 (de)
CN (1)	CN1189216C (de)
AR (1)	AR017120A1 (de)
AT (1)	ATE230611T1 (de)
AU (1)	AU734695B2 (de)
BG (1)	BG64749B1 (de)
BR (1)	BR9812469A (de)
CA (1)	CA2269923C (de)
CZ (1)	CZ301326B6 (de)
DE (1)	DE69810612T2 (de)
DK (1)	DK0981375T3 (de)
EA (1)	EA004700B1 (de)
ES (1)	ES2187062T3 (de)
HR (1)	HRP980499A2 (de)
HU (1)	HUP9701554D0 (de)
IL (1)	IL135055A (de)
LT (1)	LT4736B (de)
LV (1)	LV12493B (de)
NO (1)	NO325294B1 (de)
NZ (1)	NZ503302A (de)
PL (1)	PL193067B1 (de)
PT (1)	PT981375E (de)
RO (1)	RO118695B1 (de)
RS (1)	RS50102B (de)
SI (1)	SI20189B (de)
SK (1)	SK284683B6 (de)
TR (1)	TR200001545T2 (de)
TW (1)	TWI222365B (de)
WO (1)	WO1999013914A1 (de)
ZA (1)	ZA988585B (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5439686A (en) *	1993-02-22	1995-08-08	Vivorx Pharmaceuticals, Inc.	Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
GB9526733D0 (en)	1995-12-30	1996-02-28	Delta Biotechnology Ltd	Fusion proteins
US8137684B2 (en) *	1996-10-01	2012-03-20	Abraxis Bioscience, Llc	Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en)	1997-06-27	2014-10-07	Abraxis Bioscience, Llc	Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HUP9701554D0 (en) *	1997-09-18	1997-11-28	Human Oltoanyagtermeloe Gyogys	Pharmaceutical composition containing plazma proteins
WO2000047187A1 (en) *	1999-02-11	2000-08-17	Kinetana Inc.	Serum albumin-based parenteral formulations of polyene macrolides
DE60023324T2 (de)	1999-09-16	2006-07-20	Novo Nordisk A/S	Zusammensetzung zur in-vitro befruchtung
AU2001253336A1 (en) *	2000-04-10	2001-10-23	Teva Pharmaceutical Industries Ltd.	Method 0f administration of paclitaxel-plasma protein formulation
AU2001253334A1 (en) *	2000-04-10	2001-10-23	Teva Pharmaceutical Industries Ltd.	Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
EP1274720A4 (de)	2000-04-12	2004-08-18	Human Genome Sciences Inc	Albumin enthaltende fusionsproteine
US6946134B1 (en)	2000-04-12	2005-09-20	Human Genome Sciences, Inc.	Albumin fusion proteins
US7507413B2 (en)	2001-04-12	2009-03-24	Human Genome Sciences, Inc.	Albumin fusion proteins
CA2445763A1 (en) *	2001-05-01	2002-11-07	Angiotech Pharmaceuticals Inc.	Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
PT1463751E (pt)	2001-12-21	2013-08-26	Human Genome Sciences Inc	Proteínas de fusão de albumina
MXPA05000615A (es)	2002-07-16	2005-11-17	Medexis S A	Conjugados esteroideos, preparacion de los mismos y usos de los mismos.
GR1004274B (el)	2002-07-16	2003-06-23	Medexis ��	Συμπλοκα στεροειδων ορμονων με πρωτεινες: νεες ουσιες για την ειδικη ανιχνευση και καταστροφη καρκινικων κυτταρων προερχομενων απο στερεους ογκους και αιματολογικες κακοηθειες
AU2003262025A1 (en) *	2002-09-12	2004-04-30	Nihon Medi-Physics Co., Ltd.	Preparation for controlling binging of drug to plasma protein
EP1585548B1 (de)	2002-12-09	2018-06-27	Abraxis BioScience, LLC	Zusammensetzungen, pharmakologisch wirksame agenzien enthaltend und wirkstofffreigabemethoden
CA2513213C (en)	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
US20050079546A1 (en) *	2003-05-01	2005-04-14	Dasa Lipovsek	Serum albumin scaffold-based proteins and uses thereof
US20040225022A1 (en) *	2003-05-09	2004-11-11	Desai Neil P.	Propofol formulation containing reduced oil and surfactants
US7659310B2 (en)	2004-04-27	2010-02-09	Formatech, Inc.	Methods of enhancing solubility of agents
US7345093B2 (en)	2004-04-27	2008-03-18	Formatech, Inc.	Methods of enhancing solubility of compounds
US20050277584A1 (en) *	2004-06-09	2005-12-15	Allergan, Inc.	Pharmaceutical compositions comprising cyclosporins
WO2006035443A2 (en) *	2004-09-29	2006-04-06	Tel Hashomer Medical Research Infrastructure And Services Ltd.	Monitoring of convection enhanced drug delivery
US20060198891A1 (en)	2004-11-29	2006-09-07	Francois Ravenelle	Solid formulations of liquid biologically active agents
RU2283133C1 (ru) *	2005-06-03	2006-09-10	Общество С Ограниченной Ответственностью "Ферон"	Лечебное средство
US7507842B2 (en)	2005-08-12	2009-03-24	Radiorx, Inc.	Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
EP2061440A2 (de)	2007-04-04	2009-05-27	Sigmoid Pharma Limited	Pharmazeutische tacrolimus-zusammensetzung
ES2963291T3 (es)	2007-04-26	2024-03-26	Sublimity Therapeutics Ltd	Fabricación de múltiples minicápsulas
JPWO2009116557A1 (ja) *	2008-03-21	2011-07-21	富士フイルム株式会社	薬剤含有組成物
CN101658516B (zh) *	2008-08-26	2011-10-05	齐鲁制药有限公司	紫杉醇类药物组合物及其制备方法
ES2530049T3 (es)	2009-05-18	2015-02-26	Sigmoid Pharma Limited	Composición que comprende gotas de aceite
BR112012002963A2 (pt)	2009-08-12	2017-10-24	Sigmoid Pharma Ltd	composições imunomoduladoras compreendendo uma matriz de polímero e uma fase oleosa
US10143652B2 (en)	2009-09-23	2018-12-04	Curirx Inc.	Methods for the preparation of liposomes
WO2011038068A1 (en)	2009-09-23	2011-03-31	Formatech, Inc.	Methods for the preparation of liposomes
CA2784826A1 (en) *	2009-12-18	2011-06-23	Exodos Life Sciences Limited Partnership	Methods and compositions for stable liquid drug formulations
EP2531173B1 (de) *	2010-02-03	2018-09-26	Oncbiomune, L.L.C.	Taxan- und taxoidproteinzusammensetzungen
AR093275A1 (es)	2010-03-17	2015-05-27	Centro De Excelencia En Productos Y Procesos De Cordoba (Ceprocor)	Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos
GB201020032D0 (en)	2010-11-25	2011-01-12	Sigmoid Pharma Ltd	Composition
GB201212010D0 (en)	2012-07-05	2012-08-22	Sigmoid Pharma Ltd	Formulations
GB201319791D0 (en)	2013-11-08	2013-12-25	Sigmoid Pharma Ltd	Formulations
AU2015232994B2 (en)	2014-03-18	2020-05-28	Izun Pharmaceuticals Corp.	Protein-bound cannabinoid compositions
JP6629840B2 (ja)	2014-05-08	2020-01-15	パノプテス・ファーマ・ゲーエムベーハー	眼の疾患および障害を処置するための化合物
EA036036B1 (ru)	2014-11-07	2020-09-16	Сигмойд Фарма Лимитед	Композиции, содержащие циклоспорин
AR100034A1 (es)	2015-01-30	2016-09-07	Consejo Nac De Investig Científicas Y Técnicas (Conicet)	Una composición farmacéutica soluble en agua que comprende, al menos, una sustancia terapéuticamente activa y, al menos, una sustancia con capacidad para formar micelas
EP3978618A1 (de) *	2015-05-08	2022-04-06	Spectral Platforms, Inc.	Albuminbasierte nichtkovalente komplexe und verfahren zur verwendung davon
US10500285B2 (en)	2015-05-15	2019-12-10	Zhuhai Beihai Biotech Co., Ltd.	Docetaxel and human serum albumin complexes
WO2016205654A1 (en) *	2015-06-18	2016-12-22	Aquarius Biotechnologies, Inc.	Compositions and methods for treating inflammatory disease or conditions
US20170128480A1 (en) *	2015-11-09	2017-05-11	Max A. Cayo	Cardiac Glycosides for the Treatment of Hypercholesterolemia
SG11201805942UA (en)	2016-01-11	2018-08-30	Epicentrx Inc	Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
EP4019023A1 (de) *	2016-08-03	2022-06-29	Zhuhai Beihai Biotech Co., Ltd.	Formulierungen von fosaprepitant und aprepitant
CN115487312B (zh)	2016-10-27	2025-02-07	珠海贝海生物技术有限公司	多西他赛和人血清白蛋白的中性pH组合物
AU2018231789B2 (en)	2017-03-09	2024-02-22	Izun Pharmaceuticals Corp.	Stabilized protein-bound cannabinoid compositions
EP3602065A4 (de)	2017-03-20	2020-12-23	Spectral Platforms, Inc.	Spektroskopische verfahren zur detektion und charakterisierung von mikroorganismen
KR102869384B1 (ko)	2017-07-07	2025-10-15	에피센트알엑스, 인코포레이티드	치료제의 비경구 투여를 위한 조성물
WO2019164593A2 (en)	2018-01-08	2019-08-29	Epicentrx, Inc.	Methods and compositions utilizing rrx-001 combination therapy for radioprotection
WO2019170848A1 (en) *	2018-03-09	2019-09-12	Panoptes Pharma Ges.M.B.H.	Ophthalmic formulation
EP3811982A1 (de) *	2019-10-25	2021-04-28	Université de Strasbourg	Biomaterial auf proteinbasis mit viskoelastischem verhalten, verfahren zur herstellung davon und verwendungen davon
US20230190699A1 (en)	2020-02-04	2023-06-22	Zhuhai Beihai Biotech Co., Ltd.	Formulations of docetaxel
CN111529506B (zh) *	2020-05-18	2021-09-03	同济大学	一种两性霉素b白蛋白纳米制剂及其制备方法和应用
US11739166B2 (en)	2020-07-02	2023-08-29	Davol Inc.	Reactive polysaccharide-based hemostatic agent
US12161777B2 (en)	2020-07-02	2024-12-10	Davol Inc.	Flowable hemostatic suspension
CN116744984A (zh)	2020-12-28	2023-09-12	达沃有限公司	包含蛋白质和多官能化改性的基于聚乙二醇的交联剂的反应性干粉状止血材料
US20240199721A1 (en) *	2021-06-29	2024-06-20	Genecell Biotech Inc.	Plant cell line for producing albumin at high efficiency and use thereof
CN114544926A (zh) *	2021-12-02	2022-05-27	浙江鑫科医疗科技有限公司	一种血清蛋白稳定剂
CN115236216B (zh) *	2022-06-07	2024-03-01	合肥和合医疗科技有限公司	高效液相色谱串联质谱检测全血中免疫抑制剂的试剂盒，其制备方法和检测方法
CN116212639A (zh) *	2023-02-28	2023-06-06	湖南科伦制药有限公司	一种去除药液中有机溶剂的方法及系统
CN116297963B (zh) *	2023-03-24	2024-12-27	四川汇宇制药股份有限公司	一种白蛋白结合型紫杉醇注射剂中辛酸钠含量的检测方法
CN120789284A (zh) *	2025-09-18	2025-10-17	通化安睿特生物制药股份有限公司	一种包载环孢菌素a的白蛋白结合型药物及制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS4833013A (de) *	1971-08-30	1973-05-07
DE2653534C2 (de) *	1975-12-22	1986-08-28	Baxter Travenol Laboratories, Inc., Deerfield, Ill.	Feste Antihämophilen-Faktor-Präparation und Verfahren zu ihrer Herstellung
JPS58216126A (ja) *	1982-06-11	1983-12-15	Ono Pharmaceut Co Ltd	可容化製剤
DE3702105A1 (de) *	1987-01-24	1988-08-04	Bayer Ag	Parenterale loesung
US5051406A (en) *	1987-03-04	1991-09-24	Nippon Hypox Laboratories Incorporated	Pharmaceutical composition using albumin as a carrier and process for producing the same
JPS63215640A (ja) *	1987-03-04	1988-09-08	Nippon Hai Potsukusu:Kk	易吸収性抗炎症剤及びその製造方法
CA2086874E (en)	1992-08-03	2000-01-04	Renzo Mauro Canetta	Methods for administration of taxol
US5356927A (en) *	1992-12-02	1994-10-18	Thomas Jefferson University	Methods of treating plasmodium and babesia parasitic infections
US5916596A (en) *	1993-02-22	1999-06-29	Vivorx Pharmaceuticals, Inc.	Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en)	1993-02-22	1995-08-08	Vivorx Pharmaceuticals, Inc.	Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
GB9510716D0 (en) *	1995-05-26	1995-07-19	Pharmacia Spa	Substituted camptothecin derivatives and process for their preparation
TR199600775A2 (tr)	1996-09-27	1997-09-21	Tureks Turunc Madencilik Ic Ve	Taslara eskitilmis görüntü kazandirilmasi icin bir yöntem.
US5776912A (en) *	1996-12-20	1998-07-07	Schering Corporation	Lipophilic oligosaccharide antibiotic compositions
HUP9701554D0 (en) *	1997-09-18	1997-11-28	Human Oltoanyagtermeloe Gyogys	Pharmaceutical composition containing plazma proteins
ITMI20001107A1 (it) *	2000-05-18	2001-11-18	Acs Dobfar Spa	Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel

1997
- 1997-09-18 HU HU9701554A patent/HUP9701554D0/hu unknown
1998
- 1998-09-10 HR HRP9701554A patent/HRP980499A2/hr not_active Application Discontinuation
- 1998-09-17 SI SI9820067A patent/SI20189B/sl active Search and Examination
- 1998-09-17 AT AT98946629T patent/ATE230611T1/de active
- 1998-09-17 IL IL13505598A patent/IL135055A/en not_active IP Right Cessation
- 1998-09-17 KR KR1020007002810A patent/KR100587962B1/ko not_active Expired - Fee Related
- 1998-09-17 CN CNB988092514A patent/CN1189216C/zh not_active Expired - Fee Related
- 1998-09-17 TR TR2000/01545T patent/TR200001545T2/xx unknown
- 1998-09-17 AU AU93623/98A patent/AU734695B2/en not_active Ceased
- 1998-09-17 NZ NZ503302A patent/NZ503302A/en unknown
- 1998-09-17 JP JP51757699A patent/JP2001508806A/ja not_active Withdrawn
- 1998-09-17 SK SK329-2000A patent/SK284683B6/sk not_active IP Right Cessation
- 1998-09-17 ES ES98946629T patent/ES2187062T3/es not_active Expired - Lifetime
- 1998-09-17 WO PCT/HU1998/000086 patent/WO1999013914A1/en not_active Ceased
- 1998-09-17 DK DK98946629T patent/DK0981375T3/da active
- 1998-09-17 PT PT98946629T patent/PT981375E/pt unknown
- 1998-09-17 CA CA002269923A patent/CA2269923C/en not_active Expired - Lifetime
- 1998-09-17 RS YUP-166/00A patent/RS50102B/sr unknown
- 1998-09-17 RO ROA200000315A patent/RO118695B1/ro unknown
- 1998-09-17 EA EA200000331A patent/EA004700B1/ru not_active IP Right Cessation
- 1998-09-17 CZ CZ20000952A patent/CZ301326B6/cs not_active IP Right Cessation
- 1998-09-17 BR BR9812469-2A patent/BR9812469A/pt not_active Application Discontinuation
- 1998-09-17 PL PL339369A patent/PL193067B1/pl unknown
- 1998-09-17 DE DE69810612T patent/DE69810612T2/de not_active Expired - Lifetime
- 1998-09-17 EP EP98946629A patent/EP0981375B1/de not_active Expired - Lifetime
- 1998-09-18 AR ARP980104659A patent/AR017120A1/es not_active Application Discontinuation
- 1998-09-18 ZA ZA9808585A patent/ZA988585B/xx unknown
- 1998-09-18 TW TW087115619A patent/TWI222365B/zh not_active IP Right Cessation
1999
- 1999-04-27 US US09/299,562 patent/US6743826B1/en not_active Expired - Lifetime
2000
- 2000-03-14 LV LVP-00-38A patent/LV12493B/en unknown
- 2000-03-16 BG BG104245A patent/BG64749B1/bg unknown
- 2000-03-16 NO NO20001371A patent/NO325294B1/no not_active IP Right Cessation
- 2000-03-17 LT LT2000018A patent/LT4736B/lt not_active IP Right Cessation
2003
- 2003-01-21 US US10/349,492 patent/US7119124B2/en not_active Expired - Lifetime
2004
- 2004-03-17 US US10/802,528 patent/US7501455B2/en not_active Expired - Fee Related
2006
- 2006-10-10 US US11/546,518 patent/US20070232536A1/en not_active Abandoned
2009
- 2009-02-09 US US12/322,997 patent/US8946167B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US8946167B2 (en)	2015-02-03
ZA988585B (en)	2000-03-13
PL193067B1 (pl)	2007-01-31
NO20001371L (no)	2000-05-18
EP0981375A1 (de)	2000-03-01
LV12493A (en)	2000-06-20
US6743826B1 (en)	2004-06-01
HUP9701554D0 (en)	1997-11-28
EP0981375B1 (de)	2003-01-08
PL339369A1 (en)	2000-12-18
US20070232536A1 (en)	2007-10-04
TWI222365B (en)	2004-10-21
IL135055A (en)	2004-09-27
AU734695B2 (en)	2001-06-21
KR20010052072A (ko)	2001-06-25
US7501455B2 (en)	2009-03-10
CN1270529A (zh)	2000-10-18
KR100587962B1 (ko)	2006-06-13
IL135055A0 (en)	2001-05-20
US7119124B2 (en)	2006-10-10
CA2269923C (en)	2003-07-22
DE69810612D1 (de)	2003-02-13
DE69810612T2 (de)	2003-10-02
AR017120A1 (es)	2001-08-22
US20050064028A1 (en)	2005-03-24
BG104245A (en)	2000-11-30
SI20189A (sl)	2000-10-31
NZ503302A (en)	2001-08-31
CZ2000952A3 (cs)	2000-09-13
EA004700B1 (ru)	2004-06-24
SK3292000A3 (en)	2000-08-14
CA2269923A1 (en)	1999-03-25
AU9362398A (en)	1999-04-05
NO325294B1 (no)	2008-03-17
BG64749B1 (bg)	2006-02-28
HRP980499A2 (en)	1999-12-31
PT981375E (pt)	2003-04-30
JP2001508806A (ja)	2001-07-03
ATE230611T1 (de)	2003-01-15
BR9812469A (pt)	2002-02-05
ES2187062T3 (es)	2003-05-16
SK284683B6 (sk)	2005-09-08
LT4736B (lt)	2000-12-27
EA200000331A1 (ru)	2000-10-30
US20100076008A1 (en)	2010-03-25
YU16600A (sh)	2003-08-29
TR200001545T2 (tr)	2000-10-23
CN1189216C (zh)	2005-02-16
NO20001371D0 (no)	2000-03-16
US20040014655A1 (en)	2004-01-22
WO1999013914A1 (en)	1999-03-25
DK0981375T3 (da)	2003-05-05
RS50102B (sr)	2009-01-22
LT2000018A (en)	2000-08-25
RO118695B1 (ro)	2003-09-30
SI20189B (sl)	2007-10-31
CZ301326B6 (cs)	2010-01-20

Publication	Publication Date	Title
AU734695B2 (en)	2001-06-21	Pharmaceutical compositions containing plasma protein
Zhao et al.	2017	A rapid albumin-binding 5-fluorouracil prodrug with a prolonged circulation time and enhanced antitumor activity
JP2003534265A (ja)	2003-11-18	生物学的に活性な親水性化合物を非経口的に投与するための徐放性薬剤組成物
US20120039983A1 (en)	2012-02-16	Amphiphilic macromolecule-lipid complexes
JP2001524990A (ja)	2001-12-04	リポソームに封入されたタキサンの投与方法
JPH09512261A (ja)	1997-12-09	タキサン系の誘導体に基づく製薬組成物
EP1701699B1 (de)	2011-07-13	Pharmazeutische Zusammensetzungen eines A2a Rezeptorantagonisten
EP3453390A1 (de)	2019-03-13	Pharmazeutische zusammensetzung mit polymerisiertem wirkstoff
HU223974B1 (hu)	2005-03-29	Plazma protein tartalmú gyógyszerkészítmények és eljárás előállításukra
KR20220045203A (ko)	2022-04-12	암 치료에 따른 화학요법-유도된 말초 신경병증 치료를 위한 palm
MXPA00002561A (en)	2001-11-21	Pharmaceutical compositions containing plasma protein
WO2005017079A1 (en)	2005-02-24	Process for the purification of non-ionic solvants for stabilized injectable pharmaceutical formulaitons